Please note: This website includes an accessibility system. Press Control-F11 to adjust the website to people with visual disabilities who are using a screen reader; Press Control-F10 to open an accessibility menu.

Considerations in the Evaluation of Real-World Evidence for Patients with Multiple Myeloma: Efficacy and Safety Considerations to Inform Therapy

Wednesday, April 13, 2022

6:30PM – 7:30PM ET

Please note this TeleECHO program is 6:30PM Eastern, 5:30PM Central, 4:30PM Mountain and 3:30PM Pacific.

PROGRAM OVERVIEW

This live virtual TeleECHO program will explore the role of real-world evidence in informing management decisions of elderly and frail patients with relapsed and refractory multiple myeloma (RRMM). A brief didactic presentation will discuss prognostic features and key management considerations for the elderly and frail patient populations. A summary of clinical trial data and real world evidence to inform treatment selection in the first-line and relapse settings will also be presented. Interactive case studies will illustrate strategies for patient counseling and treatment selection in elderly and frail patients with RRMM.

Presenting Faculty:
Amrita Krishnan, MD
Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research
Professor, Department of Hematology & Hematopoietic Cell Transplantation
Chief, Division of Multiple Myeloma
Department of Hematology and Hematopietic Cell Transplantation
City of Hope Cancer Center
Duarte, CA

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Evaluate considerations in the management of multiple myeloma in elderly and frail populations, including features of the prognosis and prognostic evaluation of these patients
  • Summarize clinical trial outcomes and the role of real-world evidence in informing treatment decisions in patients who are less likely to be considered for clinical trial enrollment
  • Analyze clinical trial outcomes and real-world evidence to inform patient counseling and treatment decisions in frail and elderly patients with multiple myeloma

Target Audience

This activity is designed to meet the educational needs of medical oncologists, hematologists, nurse practitioners, pharmacists, and other members of the multidisciplinary oncology care team.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live virtual activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with multiple myeloma.

CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com